Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m Newly Diagnosed AML Treated with IVO + AZA in the AGILE Study

Name: Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m Newly Diagnosed AML Treated with IVO + AZA in the AGILE Study
Uploaded: 2023-01-12T14:00:30.690Z
Description: Pau Montesinos, MD discusses key updates from the global phase 3 AGILE study, as presented at the 2022 American Society of Hematology Annual Meeting, and speaks to the clinical implications of these data.

January 12, 2023

Pau Montesinos, MD, PhD

Video

Pau Montesinos, MD discusses key updates from the global phase 3 AGILE study, as presented at the 2022 American Society of Hematology Annual Meeting, and speaks to the clinical implications of these data.